DEMO ENVIRONMENT · TRIAL CLIENT TIER · 14-DAY PREVIEW · ALL DATA IS ILLUSTRATIVE — NO LIVE API CONNECTIONS
SYSTEM HEALTHY · v2.6.1
CLIENT Trial Signal Shield Command Growth Enterprise Alumni Partner FHIN Observer Contributor Researcher Institutional Community →
WELCOME · DAY 5 OF 14

Here's what verified intelligence looks like before you commit.

You're seeing a working preview of the same intelligence layer used by clinical, regulatory, and BD teams who can't afford false confidence. What would you do if you saw the next M&A signal 14 days ahead of the market?

Days Remaining
9·
Trial ends Jun 2 · Decision window open
Signals Accessed
37
3 of 12 categories previewed
Cortex Queries
4/10
6 queries remaining this month
Your Watchlist
Empty
Save signals during your trial to build your map
AIMN:ATLAS INTELLIGENCE MAP PREVIEW · DEMO ENVIRONMENT · 3 OF 32 REGIONS
You are seeing the edge of a living intelligence map
INDEXED SNAPSHOT · MAY 2026 DEMO · SAMPLE DATA
BOSTON 23 sig LONDON 19 sig BASEL 14 sig RIYADH TOKYO SINGAPORE LOCKED LOCKED LOCKED LOCKED LOCKED LOCKED 29 ADDITIONAL REGIONS SIGNAL TIER REQUIRED NORTH AMERICA · EUROPE · UNLOCKED
Boston
23 signals · 8 entities
Oncology, Neurology dominant
London
19 signals · 6 entities
Cardiovascular, Rare Disease dominant
Basel
14 signals · 5 entities
Oncology, Metabolic dominant
Top indication clusters in unlocked regions
Oncology37 signals
Neurology28 signals
Cardiovascular14 signals
You are seeing three unlocked regions from a 32-region Atlas preview. Signal tier unlocks the full map, entity-level movement, saved watchlists, and weekly verdict feeds.
Unlock full 32-region Atlas → Signal ($279/mo) What Signal includes →

Recent verified signals

3 unlocked previews · 2 locked behind Signal tier
SOURCE-TRACED · CONFIDENCE-SCORED

FDA expedited-pathway guidance update affects 7 GLP-1 programs in development

Cross-sponsor exposure across cardio-metabolic ANDAs filed Q1 2026. Two competitors already adjusting endpoint design.

REGULATORYNORTH AMERICAMETABOLIC
87% conf
4h ago
SIG-014

EMA scientific-advice memo cites new biomarker requirement for ccRCC submissions

Two ongoing Phase 3 protocols may need amendments before primary completion. PMDA expected to align within 90 days.

REGULATORYEUROPECCRCC
82% conf
9h ago
SIG-009

Three large-cap oncology sponsors quietly reorganized BD teams in same week

Pattern matches pre-acquisition reorganization timelines observed in 2023–2024 transactions. Worth a watch.

MARKETGLOBALONCOLOGY
71% conf
1d ago
SIG-022

Competitive intel: novel cardiovascular asset signals readiness for accelerated submission

Detailed sponsor identity, indication scope, and timing window available with Signal tier.

COMPETITIVENORTH AMERICACARDIOVASCULAR
🔒 SIGNAL TIER
Unlock signal

Reimbursement-policy shift in three EU markets affects diabetes pricing assumptions

Source memos, exposed sponsors, and confidence-scored downstream impact available with Signal tier.

POLICYEUROPEDIABETES
🔒 SIGNAL TIER
Unlock signal
YOUR NEXT THREE STEPS

Ready to go deeper?

Each tier adds a layer of decision protection. Pick the level that matches the cost of being wrong. No high-pressure sales — we'd rather you understand what you're buying.

Signal
$279/mo
Your first layer of verified clinical and regulatory signal protection.
  • Continuous signal stream (all 13 categories)
  • Full Atlas access · 32 regions
  • Cortex AI · 50 queries/mo
  • Saved watchlists · email alerts
Shield
$449/mo
Daily intelligence protection for professionals who cannot afford to be surprised.
  • Everything in Signal
  • Adversarial Validation on key signals
  • PROCEED / DELAY / KILL verdicts
  • Cortex AI · 150 queries/mo
Command
$749/mo
A private intelligence command layer for teams making high-consequence decisions.
  • Everything in Shield
  • SCOUT runs · custom dossiers
  • SYNAPSE sessions · expert review
  • Cortex AI · unlimited
See full pricing →